View all data FOR FREE!
Create an account today, no credit card required.
| Issue Type | XXXX |
|---|---|
| Country | United States |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2035-07-15 |
| Par Value | 1000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 288.45 |
| Coupon | 5.25 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 500 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Genentech, Inc. corporate note has a 5.25% fixed rate coupon paid on a semi-annual basis. It was issued on November 22, 2005 with an issue size of 500.00 million USD and matures on July 15, 2035 with a last coupon date of January 15, 2035. |
Genentech, Inc., founded in 1976 and headquartered in South San Francisco, California, is a pioneering biotechnology company dedicated to developing innovative medicines to treat serious medical conditions. The company is renowned for its focus on biologics and has a strong portfolio of targeted therapies for cancer and other diseases, including its flagship products such as Avastin and Herceptin.